The business philosophy and tools that revolutionized Toyota could save the ailing drug industry a lot more than just time and money. But is pharma really capable of getting lean?

BY ADAM FARBER, ULRIK SCHULZE, AND KIM WAGNER
These are turbulent times for innovative drugmakers. After years of high margins and deep pockets, the pharmaceutical and biotech industries are now in an era of slower growth and belt-tightening. But drugmakers increasingly recognize that one-time cost cutting isn’t enough—their problems run too deep for just a Band-Aid. As senior management searches for new business disciplines that will improve efficiency and productivity, the Toyota Production System and other “Lean” approaches to operational excellence look more and more appealing, with the promise of truly transformative, company-wide change. Just as Toyota revolutionized automaking with its Lean production system, pharma executives are aiming to secure their industry’s brave new future by adopting the Lean philosophy and tools.

For example, GlaxoSmithKline applied the concept of “one roof” development from carmaker Renault to its vaccines business by centralizing development in one location. The results were less waste and faster cycle time for decision-making, resulting in the launch of its HPV vaccine, Cervarix, 18 months earlier than the original projection. Other big phamas are also using Lean to get leaner—though the tendency so far has been toward greater emphasis on manufacturing processes. Last month, the Financial Times reported that AstraZeneca had hired two experts from Jaguar Land Rover to increase efficiency at one of its main factories. Nor are drugmakers the only healthcare industry looking to Lean principles and techniques. According to a September USA Today report, hospital CEOs nationwide are adopting the Toyota Production System concepts and Six Sigma to identify and eliminate waste—initiatives that are likely to expand to meet the cost-cutting requirements of healthcare reform over the next decade.

The drug industry’s need to transform its business model, operations, and culture is acute. With challenges on all sides—R&D productivity, rising costs, increasingly complex technologies and product portfolios, competition from generics, and growing regulatory scrutiny—industry market capitalization has declined by two-thirds of a trillion dollars since 2000. Unlike Toyota, which developed its Lean production system over a period of 50 years, pharma doesn’t have much time. With an unprecedented number of products going off-patent within the next three years and few blockbusters waiting in the wings, companies are under the gun as never before. If they hope to achieve breakthrough change through the Lean approach, current efforts will have to accelerate and expand.

What Lean Means

When Toyota created its Lean production system in the late 1950s, the Japanese company built a lasting competitive advantage, not just with high-quality, low-cost automobiles but through a fundamentally new approach to business. The foundation was its production system—a total view of how to design, produce, and sell cars that engage the entire company in a shared way of working and a common set of principles. Since then, Lean techniques have moved far beyond the shop floor. And still, the principles of Lean remain the same: an integrated, end-to-end process that combines the concepts of waste elimination, just-in-time inventory and information management, built-in quality, and worker involvement supported by a cultural focus on problem solving and the use of tools such as

**CASE STUDY: EARLY DRUG DEVELOPMENT**

Managing early development is a particularly complex task. Success rates are only about 25 percent because it is very hard to pick winners. Each scientist tends to view his or her own program as “most important.” Decision-making can’t be seen to be stifling innovative work. It is difficult to allocate spend at the molecule level.

One company’s Lean program focused on optimizing the value of the entire portfolio by holistically considering both the supply and demand sides of the problem. On the demand side, the company recognized that not all assets should be treated equally and, as a result, minimized work that does not answer key asset questions. On the supply side, it implemented Lean operational processes with streamlined governance and review cycles. The Lean program delivered a 15 to 25 percent first-year productivity gain, largely through managing demand.
kaizen (continuous improvement), kanban (ongoing replenishment), and poka-yoke (error-proofing).

Could Lean be what the ailing drug industry needs? As pharma executives increasingly recognize the imperative to fundamentally rethink their operations and culture, they look to other industries for new models. Lean has the power to deliver this high degree of transformation. It can streamline core processes, cut cycle times and costs, reduce waste and complexity, and engage the culture in pursuit of continuous improvement, while preserving the innovative spirit that drives the industry.

Yet Lean’s basic principles fly in the face of much of pharma’s culture. For one thing, pharma has only recently come to appreciate the values of productivity and efficiency. Years of high margins and large budgets engendered a less cost-conscious culture. Another problem is pharma’s fiercely independent functions, divisions, and geographic units. The silo mentality remains deeply entrenched at most drug companies. Yet Lean is all about teams, process thinking, and cross-functional collaboration. What’s more, Lean’s “just in time” principle is at odds with pharma’s historical “just in case” culture.

Success requires understanding and managing these challenges. For companies that are up to the task, the potential payoff is sizeable. Well-executed Lean programs in manufacturing can shorten cycle times by 60 to 90 percent, reduce inventory by 40 percent, and cut costs by 10 to 30 percent. New product development, sales force productivity, and marketing effectiveness can also improve.

The New System Blueprint

Before embarking on a Lean program, pharma companies must take to heart a critical lesson from Toyota: Start with a clearly defined business system, including distinct customer segments and their needs, processes for sourcing, developing, producing, marketing, and delivering products, and a well-designed support organization. Designing the blueprint for this system is the responsibility of senior management, not front-line employees. Once this system is in place, Lean programs can optimize it; without it, the full potential of Lean programs will never be realized.

Although the industry has made progress in shaking free from last century’s blockbuster business model, most companies are still struggling to define themselves in new, more rational terms. Unlike Toyota, which was operating within a sharply defined framework, the global drug industry is fast-changing and far-flung—and only growing more so with new customer segments, new markets in emerging economies (such as China, India, and Eastern Europe), differing regulatory requirements, customer needs, and market potential. This daunting complexity can lead to Lean programs that are poorly targeted and deliver little strategic impact.

Before applying Lean techniques, senior management should ask whether a function or activity should exist at all. Does it have value to the customer? Is it on a critical path? Projects that aren’t aligned with customer needs or business strategy may eliminate waste or improve cycle times, but the lasting effects will

CASE STUDY: CLINICAL SUPPLIES MANAGEMENT

A global pharma was wasting millions of dollars annually on unused clinical supplies—about half of all supplies the company ordered each year went unused. The problem was caused by a combination of factors: poor forecasting, an inability to track consumption, lack of standardization in packaging and labelling, and inefficient shipments by suppliers.

The company’s Lean program focused on improving clinical supplies management and eliminating excess inventory throughout the site network. (See chart, page 4.) Better forecasting tools have improved the ability to predict actual enrolment at each site, and new metrics that measure forecast accuracy keep the focus on improving performance. To further cut costs, the company standardized packaging and labelling, and consolidated shipments from suppliers. Finally, a new IT system allows people to see how much inventory is actually in stock before ordering new supplies. The company’s Lean efforts in this area deliver more than $20 million in annual savings.
Reducing Waste in Clinical Supplies Management

**Issue:** Enrollment variability difficult to manage, causing waste

- Inaccurate site enrollment forecasts:
  - Slow enrollment
  - Late enrollment

- High waste

- Low supply commutability
- Low visibility of supply consumption

- >50% of supply unused

**Outcome:** ~$20M annual net savings with Lean techniques

- Improve supply commutability
- Improve demand visibility
- Decrease excess overage

Reducing waste in clinical supplies management.

Inaccurate site enrollment forecasts:
- Slow enrollment
- Late enrollment

High waste

Low supply commutability

Low visibility of supply consumption

>50% of supply unused

**Companywide Application**

The relevance of the Lean approach to pharma is at first most evident when applied to manufacturing. In high-value areas where one output becomes an input for the next phase of the process, streamlining, standardization, and cross-functional coordination offer a solution to chronic problems such as long cycle times and excess inventory. By standardizing processes and platforms, Lean efforts can increase the productivity, efficiency, and flexibility of a global supply network. But inventory management poses special challenges. “Too much inventory” is not necessarily a bad thing when the inventory is a lifesaving drug. Moreover, stockouts in the early, high-margin days of a blockbuster drug must be avoided at all costs. But this is not true of all products. Having large stores of expired products is costly; so is wasting capacity on low-demand, low-margin products. Lean programs aim to optimize global capacity and inventory while ensuring an uninterrupted supply of needed medicine.

Many of these principles also apply to sales and marketing, where excess inventory and waste takes the form of unused research data, idle sales aids in the car trunks of sales reps, a large number of reviews in the process of developing commercial materials, or downtime of the...
sales force during visits to physician offices.

Although success of R&D is driven by innovation, other underlying processes are also critical—and lend themselves to Lean optimization. Many activities in drug discovery, development, and life cycle management are repeated, such as protocol review and approval, clinical study data processing, or medical review of sales aids. Lean can standardize and speed up these common processes, and at the same time make it easier for scientists to create customized development pathways for individual compounds.

While waste shows up typically as excess inventory in manufacturing, it can also take the form of masses of unused data in R&D and, later, in sales and marketing. These functions tend to front-load activities in an attempt to compress time lines. In R&D, this includes pre-ordering clinical supplies for future studies, conducting drug-drug or food-drug interaction studies before proof of concept, and commissioning large market research studies many years before filing.

Given the high failure rate of drug development, much of this work and capacity ends up as waste. Lean reduces this waste by focusing attention on experiments and investments that lower the risk of programs, rather than on executing a standardized new product development path with stage-gate checklists and undifferentiated investments. By embracing a “fail fast” approach to drug development and customizing the path to each compound, scientists and managers can become more thoughtful in how they evaluate risks, make decisions, and use resources.

**Lean’s Five Key Steps**

Leadership is integral to successful Lean efforts—especially in the pharma industry, where only senior management has an end-to-end view of the whole system and the authority to drive transformation. The most effective approach is a tailored, top-down model followed by broader,

### Seven Types of Waste in the R&D Process

<table>
<thead>
<tr>
<th>WASTE</th>
<th>DEFINITION</th>
<th>R&amp;D EXAMPLES</th>
</tr>
</thead>
</table>
| 1 Over-processing | Using a more expensive or otherwise valuable resource than is needed for the task | • Maintaining GLP standards in a discovery laboratory  
• Synthesizing or screening a larger number of compounds “because it’s automated” |
| 2 Over-production    | Production or acquisition of items before they are actually required       | • Running an assay just in case we need the data in the future  
• Ordering clinical supplies for phase III studies before proof of concept is achieved |
| 3 Transportation  | Each time a product is moved, it runs the risk of being damaged, lost, or delayed | • Sharing data in hard copy rather than electronically  
• Shipping compounds to multiple sites for screening assays |
| 4 Motion    | As Transportation refers to product, Motion refers to the producer or worker. This has significance to damage, wear, and safety | • Researcher using equipment located on multiple floors to conduct a single experiment  
• Team members flying around the world to get their work done |
| 5 Inventory | Work-in-progress represents a capital outlay that has not yet produced an income | • All data generated but not yet used for decision-making  
• Clinical supplies that are packaged but not labeled |
| 6 Defects | Quality defects prevent the customer from accepting the product         | • Data generated from a poorly designed study – ambiguous results  
• Any data invalidated by GLP, GMP, or GCP compliance issues |
| 7 Waiting    | Time spent by workers waiting for resources to arrive and the queue for their products to empty as well as the capital sunk in goods and services | • Medicinal chemists waiting for data back from primary ADME/Tox assays  
• Study initiation waiting for clinical supplies release |
bottom-up engagement. Once leadership has communicated its vision for a new business system, employees from throughout the organization should be encouraged to engage, understand, challenge, and come forward with their own ideas for adding customer value, continuous improvement, and greater levels of efficiency and effectiveness.

Other guidelines include:

**Start with strategy** When beginning a Lean transformation, focus on strategically relevant projects. Many pharma make the mistake of applying Lean techniques to administrative processes such as regulatory approval—an area that is notoriously slow and bureaucratic. But these redesign efforts tend to be slow. Teams are often large and cumbersome; the effort takes months, and the end result is only a shorter cycle time with fewer sign-offs. Applying the same effort to sales and operations planning, for instance, could make a lasting impact.

**Set ambitious goals** Lean programs must be far-reaching to be transformative. Don’t settle for only incremental or continuous improvements. Aim for high-value, high-impact projects that drive major improvements in performance, as these will help build momentum across the organization. To help prioritize, make sure that every activity either fulfills a customer need or shortens time to market. Don’t try to do everything at once, however. Keep scale small at first, then build on the Lean capability and expand the footprint. Broad-scale project proliferation can exhaust an organization before value is realized. Pharma doesn’t have time for this.

**Focus on the customer** Drug companies have a complex mix of customers—patients, physicians, hospitals, payers, and regulators—and the needs of each are increasingly segmented and variable. For instance, many pharma companies are serving developed economies and emerging markets from the same central organizations. Moreover, product portfolios typically are composed of both on- and off-patent drugs, even though the competitive dynamics of branded and generic markets are vastly different. Know who your key customers are, what they need, and, most important, what they’ll pay for. Encourage employees to question the status quo in order to find new ways to add customer value.

**Look beyond the silo** Too often, drug companies limit the impact of their improvement efforts by staying within the boundaries of organizational silos. Greater gains can be made through cross-functional thinking and cross-enterprise efforts. Seek to understand the business system as a whole before optimizing the pieces. This broader perspective will help people see the effect their decisions have on other areas of the organization and overall profitability. Train and motivate people to do what’s best for the system, not the silo.

**Change mind sets with metrics and incentives** Transforming old ways of thinking and behaving is the toughest challenge. To drive sustained change, performance metrics should be tied to the overall goals of the new business system. Develop new incentives and salary structures that promote teamwork and system-wide thinking. This will require looking closely at the mechanisms that reinforce the current silos and counter-productive behavior. Without addressing these fundamental issues, any gains will be short lived. For example, a “fail fast” philosophy in R&D aimed at quickly weeding out products with low potential won’t survive if the culture continues to reward progress through stage gates rather than hypothesis-driven decision-making.

Lean can help drug companies do far more with fewer resources. It can also engage and transform the pharma culture in far-reaching ways. These changes won’t happen overnight, though—it took Toyota 50 years to refine its Lean production system. Pharma doesn’t have that luxury of time, but ambitious, persistent companies with a clearly defined business system can get it right a lot faster than that—and the payoff will be worth the pain.

Adam Farber is a partner and managing director in BCG’s Boston office; he can be reached at farber.adam@bcg.com. Ulrik Schulze is a partner and managing director in BCG’s Zurich office; he can be reached at schulze.ulrik@bcg.com. Kim Wagner is a senior partner and managing director in BCG’s New Jersey office; she can be reached at wagner.kim@bcg.com